Disclaimer: Site selection, IRB review, and recruitment advertising rules vary by trial, sponsor, and jurisdiction. This guide reflects Brighter Click's experience running paid media for activated clinical trial sites and is not legal, regulatory, or clinical-operations advice. Confirm every compliance requirement with your IRB, CRO, and legal counsel before launching a site or a campaign.
Clinical trial site recruitment is the process of finding, qualifying, and activating investigator sites that can actually enroll patients on time. Site selection decides whether a trial meets its enrollment targets or stalls partway through recruitment. Pick the wrong sites and the best protocol, budget, and media plan will underperform, because the patients are not there, the staff cannot process them, or both.
This guide covers what site recruitment actually involves, what separates sites that fill from sites that stall, and where paid media fits once sites are activated. It is written for CRO operations teams, sponsor clinical directors, and site-strategy leads who make site-selection decisions.
What Clinical Trial Site Recruitment Actually Involves
Clinical trial site recruitment is the operational process of identifying candidate investigator sites, evaluating whether each one can deliver the patients a trial needs, and bringing qualified sites through activation so they can begin enrolling. It is not the same as patient recruitment, which starts after sites are live. Site recruitment determines the infrastructure patient recruitment runs on.
The process breaks into four stages: identification (building the long list of candidate sites), feasibility (testing each site's patient access, staff capacity, and regulatory readiness), selection (choosing the final network), and activation (completing contracts, IRB submissions, training, and system setup so the site can screen its first patient). Each stage has its own failure modes, covered below.
Site Identification: Building The Long List
The long list of candidate sites usually comes from three sources: CRO proprietary databases of past-performing sites, investigator networks and referrals, and disease-specific patient registries or claims data that show where eligible patients concentrate geographically.
The risk at this stage is over-indexing on past performance without checking whether the conditions that drove that performance still hold. A site that enrolled well in a previous study may have lost its principal investigator, shifted its patient mix, or taken on competing studies that now consume its coordinator capacity. Starting with geography, mapping where the eligible patient population actually lives based on epidemiology and claims data, and then overlaying site capability onto that map tends to produce a more reliable long list than starting from an investigator rolodex alone.
Site Feasibility: Testing Whether A Site Can Actually Deliver
Feasibility is where most site-selection mistakes get made. A site can look strong on paper, with good disease prevalence in its catchment, a willing PI, and past trial experience, and still fail to enroll because it lacks the coordinator hours, the IRB turnaround speed, or the competing-study bandwidth to process the patients it can access.
A feasibility assessment should test at minimum: the site's access to the target patient population (how many eligible patients it sees per month, verified against medical records or referral data rather than the PI's estimate alone), its coordinator and sub-investigator capacity relative to other active and upcoming studies, its IRB or ethics committee pathway and expected approval timeline, its experience with the therapeutic area and trial phase, and its data-entry and technology infrastructure (EDC experience, access to required equipment).
The most common feasibility failure is accepting a principal investigator's enrollment estimate at face value. Investigator estimates of how many patients they can enroll are widely acknowledged in the industry to be optimistic. The Association of Clinical Research Professionals and other industry bodies have documented this pattern repeatedly. Sites that ground their projections in actual chart reviews or EHR queries against the protocol's eligibility criteria produce more reliable forecasts than sites that estimate from memory.
Site Selection: Choosing The Final Network
Selection is the decision about which sites from the feasibility-vetted list make it into the final network. The goal is a network that distributes enrollment targets realistically across sites, rather than loading a few high-volume sites with targets they will struggle to meet while leaving geographic pockets of eligible patients uncovered.
Two common selection mistakes: concentrating too many sites in the same metro area (where they compete for the same patient pool) and selecting sites primarily on PI reputation rather than operational capacity. A well-known investigator who lacks coordinator bandwidth will under-enroll just as surely as a lesser-known PI with no patient access.
The selection should also account for the recruitment model the trial will use. If the plan includes direct-to-patient digital advertising, sites need to be able to handle inbound leads from people who may not be existing patients, which requires a different intake workflow than physician-referred enrollment. If the trial includes decentralized elements, site selection needs to factor in which sites can support hybrid or remote visit models and which cannot.
Site Activation: Getting Selected Sites To Their First Patient
Activation is the stage between selection and first-patient-in. It covers contract execution, IRB or ethics committee submission and approval, site staff training on the protocol and study systems, and setup of EDC, IVRS/IWRS, and any study-specific technology.
Activation delays are a major and often underestimated source of enrollment timeline slippage. A site that takes 12 weeks to activate instead of 6 has lost 6 weeks of enrollment runway, and that loss compounds across a multi-site network. The most frequent activation bottlenecks are contract negotiation (especially budget disagreements between the sponsor and institution), IRB review timelines (particularly at sites using a local IRB rather than a central IRB), and site staff turnover during the activation period.
Tracking activation milestones at the individual-site level, with clear escalation triggers when a site falls behind, is the standard operational fix. Sites that miss activation milestones by more than a defined threshold should trigger a replacement-site evaluation rather than indefinite waiting.
What Makes A Site Fill: The Characteristics That Predict Enrollment Success
Sites that consistently meet enrollment targets tend to share a set of operational characteristics that are measurable during feasibility, not just after the trial starts.
Verified patient access, not estimated. Sites that have run a chart review or EHR query against the protocol's eligibility criteria before committing to an enrollment target outperform sites that estimate from the PI's clinical impression. The difference between "I see about 20 of these patients a month" and "We queried our EHR and identified 47 patients currently in our system who meet criteria 1 through 5" is often the difference between a site that fills and one that does not.
Dedicated coordinator capacity. A site with a coordinator assigned to the study who is not also managing three other active trials will process referrals and screen candidates faster than one where coordinator time is shared across a heavy study load. Coordinator bandwidth is the most common operational bottleneck at otherwise strong sites.
Referral infrastructure. Sites embedded in a health system with an active referral network, where other physicians in the system are aware of the trial and can refer patients, have a built-in patient pipeline that standalone sites lack. This is especially important for trials targeting conditions diagnosed or managed by specialists, where the PI's own patient panel may not be large enough.
Prior enrollment track record, contextualized. Past performance matters, but only when adjusted for the specific study. A site that enrolled well in a Phase 3 cardiovascular trial with broad eligibility may underperform in a Phase 2 rare-disease study with narrow criteria. The relevant question is not "has this site enrolled well before" but "has this site enrolled well in studies with similar patient populations and eligibility complexity."
What Stalls A Site: Common Failure Patterns
Sites stall for a short, repeatable list of reasons. Recognizing these patterns early, ideally during feasibility rather than after activation, prevents the most common enrollment shortfalls.
Overcommitted coordinators. The site took on the study without accounting for its existing study load. Coordinators are stretched across too many protocols, screening slows, follow-up lapses, and the site's enrollment rate drops below its target within the first few months.
PI availability gaps. The principal investigator committed to the study but is not available for the time the protocol requires, whether for patient visits, adverse-event review, or sub-investigator oversight. This is especially common at academic sites where the PI has teaching, administrative, and other research obligations competing for the same hours.
Patient population mismatch. The site's patient population looked adequate during feasibility, but the protocol's eligibility criteria, once applied, exclude most of the patients the site actually sees. This happens most often when feasibility relied on diagnosis codes rather than a full-criteria chart review.
Competing studies. Another trial opened at the site after selection, targeting the same or an overlapping patient population. The competing study may offer a more attractive compensation structure, a less burdensome visit schedule, or simply reached the patient first.
Slow activation. The site cleared feasibility and selection but took so long to activate that the enrollment window shrank. By the time the site was ready to screen, other sites in the network had already enrolled a share of the easily reachable patients in overlapping catchment areas.
Where Paid Media Fits After Sites Are Activated
Paid media does not fix site-selection problems. It cannot manufacture patients at a site that lacks them, add coordinator hours to an overcommitted site, or accelerate an activation timeline stuck in contract negotiation. What it does is close the awareness gap at sites that have the patients, the staff, and the activation status to process them but are not reaching enough eligible people through physician referrals alone.
That is the gap geo-targeted digital advertising fills: paid search and paid social campaigns built around each activated site's catchment area, with creative that matches the protocol's eligibility criteria and clears IRB ad-approval review. The campaigns run site by site, so spend follows the sites that are actually live and ready to screen, not the network as a whole.
Brighter Click runs geo-targeted paid media for clinical trial patient recruitment, built to clear IRB ad-approval and FTC advertising requirements, for CROs and healthtech brands. On one CRO account, that approach scaled managed spend from $360,000 to $600,000 per month, cut cost per lead by 45.9%, and lifted click-to-conversion by 91.5%, landing in a $20 to $39 CPL range.
Book A Call With Brighter Click
Site selection decides whether a recruitment campaign has something to work with. Once the right sites are activated and ready to screen, geo-targeted paid media closes the awareness gap between the patients who qualify and the sites that need them.
For CROs evaluating recruitment partners before or alongside site activation, compare vetted clinical trial patient recruitment companies.
Brighter Click builds and manages geo-targeted paid media campaigns for CROs and healthtech sponsors, cleared through IRB ad-approval and FTC advertising review. See what a CRO marketing engagement includes, or book a call to walk through your current site network and where recruitment media can close the gap.
FAQ
What Is Clinical Trial Site Selection?
Clinical trial site selection is the process of identifying, evaluating, and choosing the investigator sites that will recruit and enroll patients for a study. It covers four stages: building a long list of candidate sites, running feasibility assessments, selecting the final network, and activating sites through contracts, IRB approval, and training. The quality of site selection directly determines whether a trial meets its enrollment targets.
How Do You Select A Good Clinical Trial Site?
A good clinical trial site has verified access to enough eligible patients (confirmed through chart reviews or EHR queries, not PI estimates alone), dedicated coordinator capacity that is not overcommitted to other studies, a clear IRB or ethics committee pathway, and experience with the therapeutic area and trial phase. Sites embedded in health systems with active referral networks have an additional advantage, because other physicians can route eligible patients to the study.
Why Do Clinical Trial Sites Fail To Enroll?
The most common reasons are overcommitted coordinators, principal investigator availability gaps, a mismatch between the site's patient population and the protocol's actual eligibility criteria, competing studies that target the same patients, and slow activation that shrinks the enrollment window. Most of these are identifiable during feasibility if the assessment tests operational capacity rather than relying on PI enthusiasm alone.
What Is The Difference Between Site Recruitment And Patient Recruitment?
Site recruitment is the process of finding and activating investigator sites. Patient recruitment is the process of finding and enrolling patients at those sites. Site recruitment comes first and sets the infrastructure that patient recruitment runs on. A trial with strong patient-recruitment tactics will still underperform if its sites lack the patient access or staff capacity to process the candidates those tactics generate.
How Long Does It Take To Activate A Clinical Trial Site?
Activation timelines vary widely, but common industry benchmarks cite ranges of several weeks to several months from site selection to first-patient-in, depending on contract complexity, IRB review pathway (central vs. local), and site staff readiness. Activation delays are a major source of enrollment timeline slippage and should be tracked at the individual-site level with clear escalation triggers.
What Is A Site Feasibility Assessment?
A site feasibility assessment tests whether a candidate site can realistically deliver the patients a trial needs. It evaluates the site's access to the target patient population, coordinator and sub-investigator capacity, IRB pathway, therapeutic-area experience, and technology infrastructure. The most common feasibility mistake is accepting the principal investigator's enrollment estimate without verifying it against medical records or EHR data.
How Does Geo-Targeted Advertising Work With Clinical Trial Sites?
Geo-targeted advertising runs paid search and paid social campaigns around each activated site's catchment area, reaching eligible patients who might not learn about the trial through physician referrals alone. The campaigns are site-specific, so ad spend follows the sites that are actually live and ready to screen. All creative goes through IRB ad-approval review before launch. This approach closes the awareness gap at operationally ready sites without trying to fix upstream site-selection problems that advertising cannot solve.
